Skip to main content

Day: March 10, 2026

Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

– Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 – – Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases – – FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia – – Funding from prominent healthcare investors expected to extend cash runway into 2028 – RESEARCH TRIANGLE PARK, N.C., March 10, 2026 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore...

Continue reading

ABM Reports Fiscal First Quarter 2026 Results and Reaffirms Fiscal 2026 Outlook

Revenue was $2.2 billion, an increase of 6.1% over the prior year, including organic growth of 5.5% Net income totaled $38.8 million, or $0.64 per diluted share, as compared to $43.6 million or $0.69 in the prior year Adjusted net income was $50.4 million, or $0.83 per diluted share, versus $55.3 million, or $0.87, in the prior year Adjusted EBITDA was $117.8 million, versus $120.6 million last year Operating cash flow was $62.0 million and free cash flow totaled $48.9 million, both up significantly over the prior year The Company repurchased $91.1 million of common stock during the quarter at an average price of $44.13 per shareNEW YORK, March 10, 2026 (GLOBE NEWSWIRE) — ABM (NYSE: ABM), a leading provider of facility, engineering and infrastructure solutions, today announced financial results for its fiscal first quarter...

Continue reading

NIO Inc. Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results

Quarterly Adjusted Profit From Operations (non-GAAP) Reached RMB1,251.3 Million (US$178.9 Million)i Quarterly Total Revenues Reached RMB34,650.2 Million (US$4,954.9 Million)iQuarterly Vehicle Deliveries Were 124,807 Units Full Year Total Revenues Reached RMB87,487.5 Million (US$12,510.5 Million) Full Year Vehicle Deliveries Were 326,028 Units SHANGHAI, China, March 10, 2026 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025. Operating Highlights for the Fourth Quarter and Full Year of 2025Vehicle deliveries were 124,807 in the fourth quarter of 2025, representing an increase of 71.7% from the fourth quarter...

Continue reading

Reliance, Inc. Subsidiary AMI Metals, Inc. Awarded Significant Government Infrastructure and Defense Projects

Multi-year contract with U.S. Department of Homeland Security (“DHS”) for up to $2.24 billion to provide steel and steel logistics support services Five-year IDIQ contract for up to $654 million to supply aluminum plate across multiple Lockheed Martin Corporation (“Lockheed Martin”) defense platformsPHOENIX, March 10, 2026 (GLOBE NEWSWIRE) — Reliance, Inc. (NYSE: RS) announced today that its wholly-owned subsidiary, AMI Metals, Inc. (“AMI”) has been awarded two significant contracts for United States government infrastructure and defense projects, reinforcing the Company’s position as a trusted partner in the aerospace and defense market.AMI was awarded a multi-year contract by the United States DHS to provide steel and steel logistics support services for the construction of the border wall for a total maximum estimated value...

Continue reading

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapiesIncreased focus on PD-L11/VEGF-A bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers SquibbFull year 2025 revenues of €2.9 billion2, net loss of €1.1 billion (adjusted3 net loss of €0.1 billion) and diluted loss per share of €4.70 ($5.314) (adjusted3 diluted loss per share of €0.48 ($0.554))Strong financial position continues to de-risk execution with cash, cash equivalents and security investments of €17.2 billion5 Expect 2026 total revenues of €2.0 billion to €2.3 billion, adjusted3 R&D expenses between €2.2-2.5 billion and adjusted3 SG&A expenses7 between...

Continue reading

TransUnion Investor Day to Highlight Its Next Chapter of Growth – Innovation at Scale, Value that Endures

CHICAGO, March 10, 2026 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) will host its 2026 Investor Day today in New York City, with a simultaneous livestream for virtual attendees. The program begins at 8:30 a.m. Eastern Time (ET) and is expected to conclude at approximately 1:00 p.m. ET. The live webcast, presentation materials and a replay will be available on the TransUnion Investor Relations website at www.transunion.com/tru. A webcast replay will also be accessible following the event. During this event, TransUnion’s leaders will discuss how its transformation positions the company for accelerated innovation and value creation. Areas of focus will include TransUnion’s differentiated and proprietary data foundation, its AI-powered OneTru™ technology platform, and the drivers of growth across its complementary Credit, Marketing,...

Continue reading

Ford and Bread Financial Accelerate Customer Benefits with New Financing Program— Unlocking Enhanced Experiences and Exclusive Loyalty Rewards

Ford Rewards Visa Signature® Credit CardBread Financial and Ford today announced the new Ford Rewards Visa Signature® Credit Card.New long-term agreement includes co-brand credit card and installment loan programs, delivering tailored solutions to qualifying customers Cardholders can enjoy access to instant purchasing power, flexible payment plans and unique Ford benefitsDEARBORN, Mich. and COLUMBUS, Ohio, March 10, 2026 (GLOBE NEWSWIRE) — Ford Motor Company (NYSE: F) today announced a new long-term agreement with Bread Financial (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending and saving solutions, to launch a co-branded credit card and installment loan program. The new financing program provides flexible options to enhance the ownership experience and increase...

Continue reading

BIGG Digital Assets to Present at Canaccord Genuity’s 6th Annual Digital Assets Symposium

VANCOUVER, British Columbia, March 10, 2026 (GLOBE NEWSWIRE) — BIGG Digital Assets Inc. (“BIGG” or the “Company”) (TSXV: BIGG; OTCQB: BBKCF; WKN: A2PS9W), a leading innovator and owner of Netcoins, Blockchain Intelligence Group, and TerraZero, is pleased to announce its participation in Canaccord Genuity’s 6th Annual Digital Assets Symposium. The Canaccord Genuity Digital Assets Symposium brings together listed and high-growth digital asset companies alongside global investors and key participants in the digital asset ecosystem. The event provides an important forum for BIGG to engage with the investment community and to share its vision for the future of the Company. This is a virtual event taking place on March 10 and 11, 2026 and will include several industry leaders such as Circle, BitGo and Strategy. Fraser Matthews, CEO of...

Continue reading

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., March 10, 2026 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted continued commercial momentum for its bempedoic acid franchise, strong full-year revenue growth, and progress advancing its long-term strategic...

Continue reading

Fabrinet to Webcast Investor and Analyst Q&A Sessions at the 2026 Optical Fiber Communication Conference

BANGKOK, March 10, 2026 (GLOBE NEWSWIRE) — Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today announced that company management will host two investor and analyst Q&A sessions during the 2026 Optical Fiber Communication Conference and Exposition (OFC) in Los Angeles. The Q&A sessions are scheduled for Tuesday, March 17, 2026 from 3:00 to 3:45 p.m. PT and 4:00 to 4:45 p.m. PT. A live webcast, as well as a replay, will be accessible at https://investor.fabrinet.com/. About Fabrinet Fabrinet is a leading provider of advanced optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.